Table 3.

Tranplant biopsy pathological data.

Patient	Group	Hyaline	Glomerulitis	Glomerulopathy	Gibson PTC*	Mesangial expansion	Percent fibrosis	Percent infiltrate	Tubular atrophy	Tubulitis
1	Control	2	1	2	1	0	2	2	2	1
2	Control	2	1	2	2	0	1	0	1	1
3	Control	1	2	3	1	1	1	0	0	1
4	Control	1	2	2	2	2	1	1	1	0
5	Control	3	2	3	1	2	3	1	3	0
6	Control	3	1	2	2	1	2	1	2	0
7	Control	2	1	2	1	0	2	0	2	1
8	Control	1	2	2	2	1	2	0	2	0
9	Control	0	1	2	1	0	3	1	2	0
10	Control	2	2	3	1	1	2	1	2	0
11	Control	2	1	2	1	1	2	1	2	0
12	Control	0	1	2	2	0	1	0	1	1
13	Control	2	2	3	1	1	1	0	1	0
14	Control	2	1	3	2	1	1	0	1	0
15	Control	0	1	2	1	1	2	0	2	0
16	Control	3	1	3	2	1	0	0	0	0
17	Control	1	1	2	1	1	2	0	2	0
18	RNR	3	1	3	2	2	2	1	1	0
19	RNR	3	2	2	2	1	2	1	1	0
20	RNR	2	1	2	2	1	1	0	1	1
21	RNR	1	2	3	2	1	1	1	1	0
22	RNR	1	1	3	2	1	1	1	1	0
23	RNR	3	2	2	1	2	1	0	1	1
24	RR	1	2	2	2	0	1	2	1	0
25	RR	3	1	3	1	2	2	0	2	1
26	RR	2	2	2	2	0	1	2	1	0
27	RR	3	1	3	1	1	0	1	0	0
28	RR	2	1	1	1	1	1	2	1	1
29	RR	1	2	2	2	1	2	0	2	0
30	RR	1	2	3	1	3	1	0	1	0
31	RR	0	2	2	2	1	2	1	2	0

Control: subjects not given Rituximab; RNR: Rituximab non-responders; RR: Rituximab responders;

^*peritubular capillaries.